TIME COURSE OF ALLODYNIA IN THE CHRONIC CONSTRICTION INJURY MODEL OF NEUROPATHIC PAIN.

  • king Faisal university, College of medicine.
  • Abstract
  • References
  • Cite This Article as
  • Corresponding Author

Injury to the peripheral nerves results in chronic neuropathic pain that its mechanism is not well understood. Associated with neuropathic pain is allodynia, painful sensation to non-painful stimuli. Since the mechanism is not fully understood, there is yet no effective treatment for allodynia. The aim of this study is to monitor the time course of tactile allodynia after induced injury to the sciatic nerve. To achieve this aim, 4 Lewis rats were used. Baseline measurements were taken one day before performing chronic constrictive injury (CCI) model of neuropathic pain. Comparing with the contralateral paw, on the first day after CCI, the paw withdrawal threshold of the ipsilateral paw started to decrease, but did not reach the level of significance. The sixth day though, paw withdrawal threshold in ipsilateral was significantly different. Thus, successfully establishing allodynia. On the fifteenth day, measurements of paw withdrawal threshold increased, showing tendency to recovery from CCI. These changes may be related to different immune reactions to nerve injury. Knowing the role of different immune cells and relating them to the time course of allodynia development may give us an idea about the mechanism, and thus, an effective treatment.


  1. Michael C, Joachim S, Clifford JW. A maladaptive response of the nervous system to damage. Annual review of neuroscience. 2009;32:1 – 32.
  2. Juhl GI, Jensen TS, Norholt SE, Svensson P. Centrall sensitization phenomena after third molar surgery: a quantitative sensory testing study. Eur. J. Pain. 2008;12:116 – 27.
  3. Ducreux D, Attal N, Parker F, Bouhassira D. Mechanism of central neuropathic pain: a combined psychophysical and fMRI study in syringomyelia. Brain. 2006;129:963 – 76.
  4. Bennett G, Xie Y. A peripheral mononeuropathy in rats that produces disorders of pain sensation like those in man. Pain. 1988;33:87 – 107.
  5. Seltzer Z, Dubner R, Shir Y. A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain. 1990;43:205 – 18.
  6. Lee BH, Won R, Baik EJ, Lee SH, Moon CH. An animal model of neuropathic pain employing injury to the sciatic nerve branches. NeuroReport. 2000;11:657 – 61.
  7. Michael AT, Anna KC, Fabien M, Stephen BM. Pathophysiology of neuropathic pain: Immune cells and molecules. International Anesthesia Research Society. 2007;105(3):838-47
  8. Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol 2005;6:135-42
  9. Zue Y, Perkins NM, Tracey DJ, Geczy CL. Inflammation and hyperalgesia induced by nerve injury in the rat: a key role of mas cells. Pain 2003;105:467-79
  10. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997;77:1033-79
  11. Scapini P, Lapinet-Vera JA, Gasperini S, Calzetti F, Bazzoni F, Casatella MA. The neutrophil as a cellular source of chemokines. Immunol Rev 2000;177:195-203
  12. Clatworthy AL, Illich PA, Castro GA, Walters ET. Role of peri-axonal inflammation in the development of thermal hyperalgesia and guarding behavior in a rat model of neuropathic pain. Neurosci Lett 1995;184:5-8
  13. Witko-Sarsat V, Rieu P, Scamps-Latscha B, Lesavre P, Halbwachs Mecarelli L. Neutrophils: molecules, functions and pathophysiological aspects. Lab Invest 2000;80:617–53
  14. Faurschou M, Borregaard N. Neutrophil granules and secretory vesicles in inflammation. Microbes Infect 2003;5:1317–27
  15. Griffin JW, George R, Ho T. Macrophage systems in peripheral nerves. A review. J Neuropathol Exp Neurol 1993;52:553–60
  16. Taskinen HS, Roytta M. The dynamics of macrophage recruitment after nerve transection. Acta Neuropathol (Berl) 1997; 93:252–9
  17. Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 2004;305:1010 –13
  18. Ramer MS, French GD, Bisby MA. Wallerian degeneration is required for both neuropathic pain and sympathetic sprouting into the DRG. Pain 1997;72:71– 8
  19. Cui JG, Holmin S, Mathiesen T, Meyerson BA, Linderoth B. Possible role of inflammatory mediators in tactile hypersensitivity in rat models of mononeuropathy. Pain 2000;88:239–48
  20. Moalem G, Xu K, Yu L. T lymphocytes play a role in neuropathic pain following peripheral nerve injury in rats. Neuroscience 2004;129:767–77
  21. Giri JG, Lomedico PT, Mizel SB. Studies on the synthesis and secretion of interleukin 1. I. A 33,000 molecular weight precursor for interleukin 1. J Immunol 1985;134:343–9
  22. Ferreira SH, Lorenzetti BB, Bristow AF, Poole S. Interleukin-1 beta as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature 1988;334:698–700
  23. Follenfant RL, Nakamura-Craig M, Henderson B, Higgs GA. Inhibition by neuropeptides of interleukin-1 beta-induced, prostaglandin-independent hyperalgesia. Br J Pharmacol 1989; 98:41–3
  24. Watkins LR, Wiertelak EP, Goehler LE, Smith KP, Martin D, Maier SF. Characterization of cytokine-induced hyperalgesia. Brain Res 1994;654:15–26
  25. Zelenka M, Schafers M, Sommer C. Intraneural injection of interleukin-1beta and tumor necrosis factor-alpha into rat sciatic nerve at physiological doses induces signs of neuropathic pain. Pain 2005;116:257–63
  26. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999;18:6853–66
  27. Tegeder I, Niederberger E, Schmidt R, Kunz S, Guhring H, Ritzeler O, Michaelis M, Geisslinger G. Specific inhibition of I{kappa}B kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats. J Neurosci 2004;24:1637–45
  28. Okamoto K, Martin DP, Schmelzer JD, Mitsui Y, Low PA. Pro- and anti-inflammatory cytokine gene expression in rat sciatic nerve chronic constriction injury model of neuropathic pain. Exp Neurol 2001;169:386 –91
  29. Kleinschnitz C, Brinkhoff J, Zelenka M, Sommer C, Stoll G. The extent of cytokine induction in peripheral nerve lesions depends on the mode of injury and NMDA receptor signaling. J Neuroimmunol 2004;149:77– 83
  30. Sommer C, Petrausch S, Lindenlaub T, Toyka KV. Neutralizing antibodies to interleukin 1-receptor reduce pain associated behavior in mice with experimental neuropathy. Neurosci Lett 1999;270:25– 8
  31. Schafers M, Brinkhoff J, Neukirchen S, Marziniak M, Sommer C. Combined epineurial therapy with neutralizing antibodies to tumor necrosis factor-alpha and interleukin-1 receptor has an additive effect in reducing neuropathic pain in mice. Neurosci Lett 2001;310:113–16
  32. Wagner R, Myers RR. Schwann cells produce tumor necrosis factor alpha: expression in injured and non-injured nerves. Neuroscience 1996;73:625–9
  33. Sommer C, Schafers M. Painful mononeuropathy in C57BL/Wld mice with delayed Wallerian degeneration: differential effects of cytokine production and nerve regeneration on thermal and mechanical hypersensitivity. Brain Res 1998;784: 154–62
  34. George A, Schmidt C, Weishaupt A, Toyka KV, Sommer C. Serial determination of tumor necrosis factor-alpha content in rat sciatic nerve after chronic constriction injury. Exp Neurol 1999;160:124 –32
  35. George A, Buehl A, Sommer C. Tumor necrosis factor receptor 1 and 2 proteins are differentially regulated during Wallerian degeneration of mouse sciatic nerve. Exp Neurol 2005;192: 163– 6
  36. Murphy PG, Ramer MS, Borthwick L, Gauldie J, Richardson PM, Bisby MA. Endogenous interleukin-6 contributes to hy- persensitivity to cutaneous stimuli and changes in neuropep- tides associated with chronic nerve constriction in mice. Eur J Neurosci 1999;11:2243–53

[Asma Alsaeed, Albatoul Almulhim, Fatimah Almajed, Fatimah Majrabi and Karima Kahlat. (2017); TIME COURSE OF ALLODYNIA IN THE CHRONIC CONSTRICTION INJURY MODEL OF NEUROPATHIC PAIN. Int. J. of Adv. Res. 5 (Feb). 2286-2291] (ISSN 2320-5407). www.journalijar.com


Dr. Peace


DOI:


Article DOI: 10.21474/IJAR01/3406      
DOI URL: https://dx.doi.org/10.21474/IJAR01/3406